# ENZO BIOCHEM INC

ENZO BIOCHEM INC is a company headquartered in Farmingdale, NY, United States.

## Company overview

- **Legal name:** ENZO BIOCHEM INC
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Farmingdale, NY, United States
- **Incorporated in:** NY
- **Fiscal year end:** July 31
- **SEC CIK:** 0000316253

## About

ENZO BIOCHEM INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000316253, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2024-10-29, it reported annual revenue of USD 31,907,000; net income of USD -26,078,000; total assets of USD 85,764,000 for the fiscal period ended 2024-07-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-07-31)

- **Revenue:** $31.9M (USD 31,907,000)
- **Net income:** -$26.1M (USD -26,078,000)
- **Total assets:** $85.8M (USD 85,764,000)
- **Cash and equivalents:** $52.4M (USD 52,371,000)
- **Operating cash flow:** -$26.3M (USD -26,259,000)

### FY2023 (period ended 2023-07-31)

- **Revenue:** $31.1M (USD 31,061,000)
- **Net income:** $20.3M (USD 20,288,000)
- **Total assets:** $121.9M (USD 121,880,000)
- **Cash and equivalents:** $82.4M (USD 82,373,000)
- **Operating cash flow:** -$37.0M (USD -36,976,000)

### FY2022 (period ended 2022-07-31)

- **Revenue:** $107.1M (USD 107,071,000)
- **Net income:** -$18.3M (USD -18,261,000)
- **Total assets:** $95.9M (USD 95,857,000)
- **Cash and equivalents:** $21.6M (USD 21,603,000)
- **Operating cash flow:** -$16.6M (USD -16,590,000)
- **Later filings:** Revenue, Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-07-31)

- **Revenue:** $117.7M (USD 117,731,000)
- **Net income:** $7.9M (USD 7,875,000)
- **Total assets:** $113.7M (USD 113,691,000)
- **Cash and equivalents:** $13.5M (USD 13,524,000)
- **Operating cash flow:** $387,000 (USD 387,000)

## Recent SEC filings

- Form 8-K — filed 2025-08-20 — period 2025-08-20 — CURRENT REPORT
- Form 8-K — filed 2025-08-19 — period 2025-08-19 — CURRENT REPORT
- Form 8-K — filed 2025-06-24 — period 2025-06-24 — CURRENT REPORT
- Form 10-Q — filed 2025-06-16 — period 2025-04-30 — QUARTERLY REPORT
- Form 8-K — filed 2025-04-22 — period 2025-04-22 — CURRENT REPORT
- Form 8-K — filed 2025-04-21 — period 2025-04-21 — CURRENT REPORT
- Form 8-K — filed 2025-03-31 — period 2025-03-28 — CURRENT REPORT
- Form 8-K — filed 2025-03-18 — period 2025-03-17 — CURRENT REPORT
- Form 10-Q — filed 2025-03-17 — period 2025-01-31 — QUARTERLY REPORT
- Form 8-K — filed 2025-01-16 — period 2025-01-15 — FORM 8-K
- Form 8-K — filed 2025-01-15 — period 2025-01-13 — CURRENT REPORT
- Form 8-K — filed 2025-01-14 — period 2025-01-08 — CURRENT REPORT

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/enzo-biochem-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology